Drug Type Small molecule drug |
Synonyms CBL 514, CBL-514 |
Target |
Mechanism BAX agonists(Apoptosis regulator BAX agonists), DYRK1B inhibitors(DYRK-1 beta protein kinase inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhasePhase 2 |
First Approval Date- |
RegulationFast Track (US), Orphan Drug (EU), Orphan Drug (US) |
Molecular FormulaC14H12O3 |
InChIKeyLUKBXSAWLPMMSZ-OWOJBTEDSA-N |
CAS Registry501-36-0 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Protoporphyria, Erythropoietic | Phase 2 | US | 10 May 2023 | |
Cellulite | Phase 2 | US | 09 Jan 2023 | |
Adiposis Dolorosa | Phase 2 | US | 03 Oct 2022 | |
Subcutaneous fat disorder | Phase 2 | AU | 03 Feb 2020 |
Phase 2 | 12 | kvwadztnwa(gueyjvaffm) = dykjfdiftt kaykpvanxk (qrosvgqozk, 0.9) Met View more | Positive | 25 Apr 2024 | |||
Phase 2 | 23 | ldibnfrtgg(tmpinnvcsk) = yoxtnsmfyx wgqeqhndpr (lgtiqexmgo, 1.3) Met | Positive | 25 Apr 2024 | |||
Phase 2 | 25 | (CBL-514 320 mg) | sbqcqrncdb(vhsgbqdywf) = bctsvicbir igaurverto (nnhdytyiek, pnowqphmea - pzgxxwsjdm) View more | - | 28 Mar 2024 | ||
(CBL-514 480 mg) | sbqcqrncdb(vhsgbqdywf) = basdkhvnxq igaurverto (nnhdytyiek, tpqmiannjh - pytjovepoj) View more | ||||||
Phase 2 | 76 | mldhwgvmwf(wpkzkyhssw) = bgamlddmzt aisegihdsa (zokbecmyzs ) View more | Positive | 26 Dec 2023 | |||
Placebo | - | ||||||
Phase 2 | 76 | dvhihysbyt(zxkfgqhmpy) = nfvsmmhuad wvntivdgsu (pxfqlccnvb ) Met View more | Positive | 02 Oct 2023 | |||
Placebo | dvhihysbyt(zxkfgqhmpy) = zjcpgtmpix wvntivdgsu (pxfqlccnvb ) Met View more | ||||||
Phase 2 | 12 | anxyrwobdi(gyzadjciax) = in the high-dose group was reduced by 51.3% (p<0.0001) and 54.7% (p<0.0001) at 4 and 8 weeks after CBL-514 treatments, in the low-dose group was reduced by 40.0% (p=0.0002) and 34.7% (p<0.0001) at 4 and 8 weeks after CBL-514 treatments. dxzuxkswwb (wcakbuszpd ) Met View more | Positive | 13 Sep 2023 |